Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT01910610
Title	Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)
Acronym	STRATEGIC-1
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	GERCOR - Multidisciplinary Oncology Cooperative Group
Indications	colon adenocarcinoma rectum adenocarcinoma
Therapies	Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin
Age Groups:	adult \| senior
Covered Countries	ISR \| IRL \| FRA